Literature DB >> 7704956

Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a marker of adrenocortical tumour.

D Flecchia1, E Mazza, M Carlini, A Blatto, F Olivieri, G Serra, F Camanni, M Messina.   

Abstract

BACKGROUND AND
OBJECTIVE: Reduced serum levels of dehydroepiandrosterone sulphate (DHEAS) have been shown in patients with Cushing's syndrome resulting from adrenocortical adenoma, in contrast with normal DHEAS levels in patients with Cushing's disease. The aim of this study was to verify whether patients with incidentally discovered adrenocortical adenomas also have reduced levels of DHEAS.
DESIGN: Evaluation of serum DHEAS, serum and urinary cortisol, plasma ACTH and low dose dexamethasone suppression test in patients with adrenal incidentaloma and Cushing's syndrome. PATIENTS: Thirty-two patients with adrenal incidentaloma and, as controls, 17 patients with overt Cushing's syndrome, were studied.
RESULTS: Serum DHEAS levels lower than normal were found in 21/24 (87.5%) patients with adrenocortical incidentaloma, but in only 1/8 patients with a mass of non-adrenocortical origin. This patient had massive bilateral metastatic infiltration of both adrenal glands and primary adrenal failure. The prevalence of low DHEAS levels in the two groups was significantly different (P = 0.0001). In patients with adrenocortical incidentaloma, the prevalence of low DHEAS levels was significantly higher (P = 0.0001) than that found for some hormonal alterations indicating pre-clinical hypercortisolism (high urinary cortisol, unsuppressed serum cortisol after low dose dexamethasone administration and low plasma ACTH). Low DHEAS levels were found in all patients with Cushing's syndrome due to adrenocortical adenoma but in none of those with Cushing's disease.
CONCLUSIONS: Our results indicate that the finding of low DHEAS levels can be considered a marker of the adrenocortical origin of an adrenal incidentaloma, provided adrenal failure has been excluded.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7704956     DOI: 10.1111/j.1365-2265.1995.tb01852.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  The natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation.

Authors:  E Grossrubatscher; F Vignati; M Possa; P Lohi
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

Review 2.  The clinical evaluation of silent adrenal masses.

Authors:  B Ambrosi; E Passini; T Re; L Barbetta
Journal:  J Endocrinol Invest       Date:  1997-02       Impact factor: 4.256

Review 3.  Subclinical Cushing's syndrome.

Authors:  Massimo Terzolo; Giuseppe Reimondo; Silvia Bovio; Alberto Angeli
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

4.  Adrenal bilateral incidentaloma by reactivated histoplasmosis.

Authors:  S Lio; M Cibin; R Marcello; M A Viviani; L Ajello
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

5.  An unusual case of bilateral virilizing adrenal adenoma co-secreting androgens and cortisol.

Authors:  E Delgrange; P Goethals; A Laka; D Maiter; M Lambert
Journal:  J Endocrinol Invest       Date:  1996-06       Impact factor: 4.256

6.  Utility of plasma dehydroepiandrosterone sulphate determination in adrenal incidentalomas.

Authors:  G P Bernini; G F Argenio; M S Vivaldi; A Moretti; P Miccoli; P Iacconi; A Magagna; A Salvetti
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

Review 7.  Adrenal tumors: how to establish malignancy ?

Authors:  M Fassnacht; W Kenn; B Allolio
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

8.  Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas.

Authors:  Yoon Young Cho; Sunghwan Suh; Ji Young Joung; Hyemin Jeong; Dongmo Je; Hongseok Yoo; Taek Kyu Park; Yong-Ki Min; Kwang-Won Kim; Jae Hyeon Kim
Journal:  Korean J Intern Med       Date:  2013-08-14       Impact factor: 2.884

9.  No Postoperative Adrenal Insufficiency in a Patient with Unilateral Cortisol-Secreting Adenomas Treated with Mifepristone Before Surgery.

Authors:  Rachel M Saroka; Michael P Kane; Lawrence Robinson; Robert S Busch
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2016-07-26

Review 10.  Adrenal Incidentaloma.

Authors:  Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.